EUVIMED · CrossrefZeitschrift
Expert Opinion on Therapeutic Patents
ISSN 1354-3776 · Informa Healthcare
Neueste Artikel
Therapeutic potential of glycyrrhetinic acids: an updated patent review (2018–2024)
A patent review of anti‑VEGF antibodies for the treatment of ocular diseases (2020–present)
Allosteric anticoagulation: emerging non-orthosteric inhibitors of factor XI and factor XIa
Overcoming the blood–brain barrier for therapeutics targeting neurodegenerative diseases: a patent review (2020–present)
Global patent landscape of synthetic drugs for melasma (2015–2025): innovation trends, mechanistic shifts, and translational challenges
Aurora kinase inhibitors: an updated patent review (2021–present)
Progress with FAK inhibitors in the patent literature (2020-present)
A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021–2025)
A patent perspective of RSK inhibitors to treat cancer (2020-present)
PCSK9 inhibitors: an updated patent review 2024–2025
An updated patent review of acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease (2021–present)
Tricyclic boronic acids as broad-spectrum serine and metallo-β-lactamase inhibitors with in vitro activity against Acinetobacter baumannii : a patent evaluation (US 2025/0223303)
The future of BRD9 inhibitors: a patent perspective (2019-present)
A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020 – present)
Toll-like receptor agonists as cancer therapeutics: a patent review (2014–2024)
Rho kinase inhibitors: a patent review (2017–2023)
A patent review of IDO1 inhibitors for cancer (2023 – present): an update
A patent review of CXCR7 modulators (2019-present)
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)
JBI-802: the first orally available LSD1/HDAC6 dual inhibitor to enter clinical trials
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress
Patent landscape of small molecule inhibitors of METTL3 (2020-present)
A patent review of small molecular inhibitors targeting EGFR exon 20 insertion (Ex20ins) (2019-present)
Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review
Urease inhibitors for the treatment of H. pylori
An updated patent review of BRD4 degraders
An updated patent review on PD-1/PD-L1 antagonists (2022-present)
A patent review on hypoxia-inducible factor (HIF) modulators (2021–2023)
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)
Therapeutic potential of boswellic acids: an update patent review (2016–2023)
Jahrgänge
2026 · 422025 · 682024 · 692023 · 522022 · 662021 · 712020 · 722019 · 742018 · 772017 · 1042016 · 1102015 · 1222014 · 1142013 · 1242012 · 1002011 · 1122010 · 1192009 · 1212008 · 1042007 · 1122006 · 1172005 · 1202004 · 1702003 · 2492002 · 1322001 · 1262000 · 1491999 · 1381998 · 1331997 · 1221996 · 1411995 · 1301994 · 230
EUVIMED